Pharma Focus Asia

Becton Dickinson Unveils US$36 million (€34 million) R & D Centre in Dublin, Ireland


BD expands operations with US$4.3 million (€4 million) R&D Centre in Dublin and US$32 million (€30) million investment in Enniscorthy manufacturing plant in Ireland.


The new facility will be dedicated to advancing inaugural on-body injector device, the BD Evolve™ On-Body Injector, aligning with the growing demand for injectable drugs in the pharmaceutical pipeline. 

The new 10,600 sq. ft. R&D facility in Blackrock, accommodating 35 high-tech employees, complements the existing Limerick R&D centre with over 300 personnel.
Additionally, it will function as the regional hub for sales, technical service, and corporate functional support teams.

Furthermore, it also expands its operations with a 40,000 sq. ft. facility to manufacture a new medical technology from the Peripheral Intervention business unit. These dual investments will result in the creation of more than 85 new employment opportunities.


Name   Becton Dickinson
Type     New Construction
Budget  US$4.3 million (€4 million) R&D Centre & US$32 million (€30) million Manufacturing Plant

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference